Pulse Entdecken nav.journalClub Debatten Trends Forschende

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

CXCR2 inhibition enables NASH-HCC immunotherapy | Synapse

April 27, 2022Open Access

CXCR2 inhibition enables NASH-HCC immunotherapy

JLJack LeslieNewcastle University JMJohn B. G. MackeyCancer Research UK TJThomas JamiesonCancer Research UK

Key Points

Key points are not available for this paper at this time.

Abstract

CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.

KI fragen

Like

Bookmark

Share

View Full Paper

KI fragen

Like

Bookmark

Share

View Full Paper

Cite This Study

Leslie et al. (Wed,) studied this question.

synapsesocial.com/papers/69db23357a67537a8ba3d061 https://doi.org/https://doi.org/10.1136/gutjnl-2021-326259

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade2017 · 3,905 citations
2Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team2013 · 599 citations
3CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis2010 · 189 citations
4Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib2020 · 1,218 citations
5Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN2009 · 3,362 citations